Wang Qin, Zhu Lujian, Sheng Qiyue
Department of Infectious Diseases, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Discov Oncol. 2024 May 13;15(1):161. doi: 10.1007/s12672-024-01030-z.
The incidence and mortality of cancer is ever-increasing, which poses a significant challengesto human health and a substantial economic burden to patients. At present, chemotherapy is still a primary treatment for various cancers. However, chemotherapy kills tumors but also induces the related side effects, whichadversely impacting patient quality of life and exacerbating suffering. Therefore, there is an urgent need for new and effective treatments that can control tumor growth while reducing the side effects for patients. Arterial chemoembolization has been attracted much attentionwhich attributed to the advantage of ability to embolize tumor vessels to block blood and nutrition supplies. Thus, to achieve local tumor control, it has become an effective means of local tumor control and has been widely used in clinical practice. Despite its efficacy, conventional arterial chemoembolization techniques, limited by embolization materials, have been associated with incomplete embolization and suboptimal drug delivery outcomes. Gradually, researchers have shifted their attention to a new type of embolic material called CalliSperes drug-eluting embolic bead (DEB). DEB can not only load high doses of drugs, but also has strong sustained drug release ability and good biocompatibility. The integration of DEBs with traditional arterial chemoembolization (DEB-TACE) promises targeted vascular embolization, mitigated tumor ischemia and hypoxia, and direct intravascular chemotherapy delivery. It can prevent cancer cell differentiation and accelerate their death, meanwhile, directly injecting chemotherapy drugs into the target blood vessels reduced the blood concentration of the whole body, thus reduced the toxic and side effects of chemotherapy. Furthermore, DEB-TACE's sustained drug release capability elevates local drug concentrations at the tumor site, amplifying its antitumor efficacy. Therefore, DEB-TACE has become a hot spot in clinical research worldwide. This review introduces the pathogenesis of solid tumors, the background of research and biological characteristics of DEB, and the action mechanism of DEB-TACE, as well as its clinical research in various solid tumors and future prospects. This review aims to provide new ideas for the treatment of DEB-TACE in various solid tumors.
癌症的发病率和死亡率不断上升，这对人类健康构成了重大挑战，并给患者带来了沉重的经济负担。目前，化疗仍然是各种癌症的主要治疗方法。然而，化疗在杀死肿瘤的同时也会引发相关的副作用，这对患者的生活质量产生不利影响并加剧痛苦。因此，迫切需要新的有效治疗方法，既能控制肿瘤生长，又能减少对患者的副作用。动脉化疗栓塞术因其能够栓塞肿瘤血管以阻断血液和营养供应的优势而备受关注。因此，为了实现局部肿瘤控制，它已成为一种有效的局部肿瘤控制手段，并在临床实践中得到广泛应用。尽管其疗效显著，但传统的动脉化疗栓塞技术受栓塞材料的限制，存在栓塞不完全和药物递送效果欠佳的问题。逐渐地，研究人员将注意力转向了一种新型栓塞材料——CalliSperes药物洗脱栓塞微球（DEB）。DEB不仅可以负载高剂量的药物，还具有强大的药物持续释放能力和良好的生物相容性。将DEB与传统动脉化疗栓塞术（DEB-TACE）相结合，有望实现靶向血管栓塞、减轻肿瘤缺血缺氧以及直接进行血管内化疗给药。它可以阻止癌细胞分化并加速其死亡，同时，将化疗药物直接注入靶血管可降低全身血药浓度，从而减少化疗的毒副作用。此外，DEB-TACE的药物持续释放能力提高了肿瘤部位的局部药物浓度，增强了其抗肿瘤疗效。因此，DEB-TACE已成为全球临床研究的热点。本综述介绍了实体肿瘤的发病机制、DEB的研究背景和生物学特性、DEB-TACE的作用机制，以及其在各种实体肿瘤中的临床研究和未来前景。本综述旨在为DEB-TACE在各种实体肿瘤治疗中提供新思路。
